Clinical trial
Open access
Sep 2026
Bioavailability of a novel anti-influenza agent, onradivir granules, in healthy Chinese adults: a first-in-human study
Background Onradivir (ZSP1273) is a novel inhibitor of the RNA polymerase PB2 subunit of influenza A virus, developed for the treatment of acute uncomplicated influenza A. The onradivir tablet, launched in 2023, is intended for adult patients and is not suitable for children. This project aims to evaluate the pharmacok...
Xiao-Yi Yi, Yu-Ting Liu, Xiao-Song Wang et al.
· Frontiers in Pharmacology · 0 citations